(HealthDay)—Patients with primary restless leg syndrome who begin dopamine agonist (DA) therapy may be at increased risk for adverse psychiatric events, according to a study published in the September issue of the Journal of Clinical Sleep Medicine. Cheryl Hankin, Ph.D., from BioMedEcon in Moss Beach, California, and colleagues evaluated the association between DA initiation and